ProShares UltraShort NASDAQ Biotechnology
12 hedge funds and large institutions have $2.62M invested in ProShares UltraShort NASDAQ Biotechnology in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
9% more funds holding
Funds holding: 11 → 12 (+1)
0.27% less ownership
Funds ownership: 0.95% → 0.68% (-0.27%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
38% less capital invested
Capital invested by funds: $4.23M → $2.62M (-$1.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$681K |
| 2 |
Wolverine Trading
Chicago,
Illinois
|
+$323K |
| 3 |
Morgan Stanley
New York
|
+$138K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$70.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$850K |
| 2 |
Jane Street
New York
|
-$660K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$319K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$317K |
| 5 |
CT
CMT Trading
Chicago,
Illinois
|
-$210K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HVC
1
Healthcare Value Capital
Woodcliff Lake,
New Jersey
| $606K | +$681K | +3,125 | New |
|
|
VF
2
Virtu Financial
New York
| $479K | -$165K | -755 | -23% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $454K | -$850K | -3,898 | -63% |
|
|
4
Wolverine Trading
Chicago,
Illinois
| $283K | +$323K | +1,481 | New |
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $260K | +$43K | +197 | +17% |
|
|
6
Citadel Advisors
Miami,
Florida
| $205K | -$317K | -1,453 | -58% |
|
|
7
Morgan Stanley
New York
| $168K | +$138K | +632 | +271% |
|
|
8
UBS Group
Zurich,
Switzerland
| $63K | +$70.4K | +323 | New |
|
|
9
Simplex Trading
Chicago,
Illinois
| $47K | +$53K | +243 | New |
|
10
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $34K | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $24K | – | – | – |
|
|
FANJ
12
Financial Architects (New Jersey)
Marlton,
New Jersey
| $1K | – | – | – |
|
|
13
Jane Street
New York
| – | -$660K | -2,967 | Closed |
|
|
VKH
14
Virtu KCG Holdings
New York
| – | -$319K | -1,433 | Closed |
|
|
CT
15
CMT Trading
Chicago,
Illinois
| – | -$210K | -946 | Closed |
|
BIS Hedge Fund Activity: Q2 2017 in Review
12 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2017, worth a combined $2.62M — down 38% from $4.23M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BIS positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Healthcare Value Capital, opening a new position worth an estimated $681K. The largest seller was Tower Research Capital (TRC), cutting an estimated $850K.
- 12 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2017, up from 11 in Q1 2017.
- Funds reported $2.62M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2017, down 38% quarter-over-quarter.
- 4 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2017 and 3 closed out, a net change of +1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2017 was Healthcare Value Capital, an estimated $681K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2017 was Tower Research Capital (TRC), an estimated $850K sold.
Based on aggregated 13F filings for Q2 2017.